Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
CC transcript
Consulting agrmnt
Inv. presentation
DYNAVAX TECHNOLOGIES CORP (DVAX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance • Generated record quarterly HEPLISAV-B® vaccine net product revenue of $56 million, a 73% year-over-year increase • Full year HEPLISAV-B net product revenue guidance raised to $200 - $215 million, compared to prior range of $165 - $185 million • Cash and investments increased to $682 million at quarter end; expects positive free cash flow for full year • Conference call today at 4:30 p.m. ET/1:30 p.m. PT"
07/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/26/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/02/2023 8-K Quarterly results
02/23/2023 8-K Quarterly results
Docs: "Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance • 2022 total revenue of $723 million, up 64% from $439 million in 2021 o HEPLISAV-B® vaccine net product revenue of $126 million, representing 104% growth compared to 2021 o CpG 1018® adjuvant vaccine net product revenue of $588 million • 2023 HEPLISAV-B net product revenue anticipated to be between $165 million and $185 million, representing year-over-year revenue growth of approximately 30-50% • Increased strength of financial position with year-end cash and investments of $624 million • Conference call today at 4:30 p.m. ET/1:30 p.m. PT"
01/09/2023 8-K Investor presentation
Docs: "Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline Results • Preliminary full year 2022 HEPLISAV-B® vaccine Net Product Revenue of approximately $126 million, representing 104% growth compared to 2021 • Preliminary full year CpG 1018® adjuvant Net Product Revenue of approximately $588 million • Maintained strong financial position with year-end cash and investments of approximately $624 million • Phase 1 shingles trial results demonstrate favorable tolerability with similar vaccine response rates in CpG 1018 adjuvanted arms versus comparator vaccine EMERYVILLE, CA – January 9, 2023 –&#x202f",
"B PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 COMMERCIAL PARTNER 1, 2"
11/03/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
05/26/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/16/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
02/28/2022 8-K Quarterly results
Docs: "Dynavax Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Full Year 2022 Financial Guidance • Record 2021 total revenue of $439 million, up from $47 million for 2020 o Record full year HEPLISAV-B® net product revenue of $62 million o Record full year CpG 1018® adjuvant net product revenue of $375 million, meeting previously announced 2021 guidance • 2021 GAAP Net Income of $77 million, achieving first profitable year • Ended 2021 with $546 million cash, cash equivalents and marketable securities • Full Year 2022 CpG 1018 adjuvant revenue anticipated to be at least $550million • Conference call to be held today at 4:30 p.m. ET/1:30 p.m. PT"
12/14/2021 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Dynavax Reports Third Quarter 2021 Financial Results  Third quarter 2021 total revenue of $108.3 million o HEPLISAV-B net product revenue of $22.7 million o CpG 1018® adjuvant product revenue of $84.3 million  Increased 2021 full-year CpG 1018 revenue guidance to be between $375 and $425 million  ACIP voted unanimously to recommend that all adults 19 to 59 years of age should receive hepatitis B vaccination  Conference call to be held today at 4:30 p.m. ET/1:30 p.m. PT"
10/21/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Dynavax Technologies Corporation Non-Employee Director Compensation Policy, effective October 2021"
08/04/2021 8-K Quarterly results
Docs: "Dynavax Announces Second Quarter 2021 Financial Results"
07/07/2021 8-K Entry into a Material Definitive Agreement  Interactive Data
07/01/2021 8-K Entry into a Material Definitive Agreement  Interactive Data
06/24/2021 8-K Quarterly results
06/02/2021 8-K Quarterly results
05/26/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
04/06/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
02/19/2021 8-K Quarterly results
02/01/2021 8-K Quarterly results
01/21/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/12/2021 8-K Quarterly results
01/07/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Dynavax Announces Third Quarter 2020 Financial Results"
09/24/2020 8-K Quarterly results
09/14/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy